NCT00997997

Avelox in Complicated Skin and Skin Structure Infections

ARTOS - Avelox® in Routine Treatment of Complicated Skin and Skin Structure Infections

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 6,127 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 10 Years
• Healthy volunteers: Not accepted

Summary

This international, prospective, non-interventional, non-controlled observational study obtains data on efficacy, safety and tolerability of Avelox treatment under daily-life treatment conditions. Specifically investigated are the improvement of clinical symptoms and the duration until infection improvement and cure.Any patient with a diagnosis of complicated skin and skin structure infection (cSSSI) treated with Avelox can be documented. The observation period for each subject covers the treatment period with Avelox. For each patient, the physician documents data at an initial visit and one or two follow-up visit(s) in line with routine practice.

Conditions

• Skin Diseases, Bacterial

Interventions

Type	Name	Description
DRUG	Moxifloxacin (Avelox, BAY12-8039)	400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information

Timeline

• Start date: 2005-10-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2009-10-20
• Last updated: 2012-11-16

Locations

12 sites across 12 countries: Austria, Bulgaria, Egypt, Germany, Greece, Indonesia, Pakistan, Philippines, Saudi Arabia, Slovenia, South Korea, Taiwan